Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-06-12 pm EDT After market 04:49:22 pm
145.4 USD -0.92% Intraday chart for Johnson & Johnson 146 +0.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Johnson & Johnson Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:00 PM
Cancer victims ask court to block J&J talc bankruptcy RE
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Johnson and Johnson Talcum-Settlement Consent Judgments Filed -- Update DJ
Johnson & Johnson to Pay $700 Million in Talc Case Settlement With 43 State Prosecutors MT
J&J Talcum-Settlement Consent Judgments Filed, U.S. State AGs Say DJ
RTW Biotech portfolio company to sell subsidiary for USD1.25 billion AN
Top law firms in US opioid lawsuits to get hundreds of millions in fees RE
J&J-backed Rapport Therapeutics shares debut nearly 6% higher RE
J&J: FDA approves VELYS for knee arthroplasty CF
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
J&J-backed Rapport Therapeutics raises $136 mln in US IPO RE
Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating MT
J&J: applies to FDA for expanded indication for Prezcobix CF
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab Our Logo
J&J: successful trial for Carvykti in multiple myeloma CF
J&J: promising trial for Tecvayli in multiple myeloma CF
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case MT
J&J must pay $260 million in latest talc trial, Oregon jury says RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study CI
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer CI
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI CI
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
146.8 USD
Average target price
171.7 USD
Spread / Average Target
+17.01%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Sector Update: Health Care Stocks Gaining Thursday Afternoon